Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Rhea-AI Summary

Candel Therapeutics (Nasdaq: CADL) announced it will present multiple updates at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5-9, 2025, National Harbor, Maryland. The company will present two poster abstracts on Nov 7: one on its enLIGHTEN Discovery Platform and one on CAN-2409+valacyclovir immune responses in NSCLC. CEO Dr. Paul Peter Tak will give an invited faculty presentation and participate in a panel to present positive phase 3 CAN-2409 data in localized prostate cancer on Nov 7 at 3:55–5:35 p.m.

NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland.

Dr. Paul Peter Tak, M.D., Ph.D., FMedSci, will also present Candel’s positive phase 3 clinical trial data of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer as part of an invited faculty presentation and panel discussion on the state of the cancer "and beyond" immunotherapy field, including both opportunities and obstacles for developing the next wave of breakthrough therapeutics.

Details are as follows:

Poster Presentations

Title: Integrative discovery of a multimodal cancer immunotherapy using machine learning and viral vector engineering
Presenter: Anne Diers, Ph.D., Vice President, Research, Candel Therapeutics
Abstract Number: 893
Session Date: Friday, Nov. 7, 2025
Location: Prince George ABC Exhibit Halls – Gaylord National Resort and Convention

Title: Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC
Presenter: Daniel H. Sterman, M.D., Thomas and Suzanne Murphy Professor and Director, Multidisciplinary Pulmonary Oncology Program, NYU Langone Medical Center
Abstract Number: 513
Session Date: Friday, Nov. 7, 2025
Location: Prince George ABC Exhibit Halls – Gaylord National Resort and Convention

Invited Faculty Presentation and Panel Discussion

Title: Phase 3, Randomized, Placebo-Controlled Clinical Trial of CAN-2409 + Prodrug in Combination with Standard of Care Radiation Therapy for Newly Diagnosed, Localized Prostate Cancer with Curative Intent
Presenter: Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel Therapeutics
Session: The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics
Date/Time: Friday, Nov. 7, 2025, 3:55 - 5:35 p.m.
Location: Potomac Ballroom – Gaylord National Resort and Convention

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Regenerative Medicine Advanced Therapy Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC and prostate cancer, and both Fast Track Designation and Orphan Drug Designation to CAN-2409 for the treatment of PDAC.

CAN-3110 (linoserpaturev) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma. Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
Vice President
ICR Healthcare
CandelPR@icrhealthcare.com

FAQ

When will Candel Therapeutics (CADL) present at SITC 2025?

Candel presents on Friday, Nov 7, 2025, with poster sessions and an invited faculty presentation at 3:55–5:35 p.m.

What topics will CADL cover in its SITC 2025 posters on Nov 7?

Two posters: enLIGHTEN Discovery Platform (abstract 893) and CAN-2409+valacyclovir immune response in NSCLC (abstract 513).

Who will present Candel's phase 3 CAN-2409 data at SITC 2025?

Dr. Paul Peter Tak, President and CEO, will present positive phase 3 CAN-2409 data in localized prostate cancer.

Where and when is Dr. Tak's invited faculty presentation at SITC 2025?

Potomac Ballroom, Gaylord National Resort and Convention, Friday, Nov 7, 2025, 3:55–5:35 p.m., session: The Next Wave.

Which CADL poster discusses differential immune response in NSCLC?

Abstract 513: 'Advanced analytics identify a differential immune response to CAN-2409+valacyclovir' presented by Daniel H. Sterman, M.D., on Nov 7.

How can investors or attendees view Candel's SITC presentations?

Attend SITC 2025 in National Harbor Nov 5–9; Candel's posters and invited talk are scheduled for Nov 7 at the Gaylord National Resort and Convention.